Isigungu ngasinye sezidakamizwa sinikeza indlela ehlukile yokusebenza
Okwamanje, ukwelashwa okukhona kuphela kwesifo se- celiac kuyinto yokudla okungenayo i-gluten . Kodwa lokho kungase kushintshwe maduzane.
Abakhiqizi abaningi bezidakamizwa okwamanje benza ukuvivinya kwemitholampilo ukuhlola ukuphepha nokusebenza kwamanxusa amaningi wezinzwa zamanoveli. Ngamunye unendlela ehlukile nendlela yokusebenza (MOA). Kuthemba ukuthi ngokuvimbela inqubo yalesi sifo, kungenzeka ngelinye ilanga sisuse ngokuphelele isifo se-celiac esiqhingini sezifo ezizimele .
Phakathi kwalabo abathathu abazethembisayo kakhulu emgqeni wezidakamizwa:
I-INN-202 (i-Larazotide Acetate)
Ukuvuselela i-INN-202 ye-Pharmaceutical (i-larazotide acetate) yisidakamizwa esisebenzisa i- enzyme enamandla yokugaya ebonakala ikwazi ukuphula i-gluten ngaphambi kokuba isimiso somzimba wakho somzimba singasabela kuso. Imiphumela yesivivinyo sesiguli sesibili se- Phase II yayithembisa futhi yabonisa ukuthi lesi sidakamizwa sasiphephile futhi sibekezeleleka. I-MOA yombili yezidakamizwa inciphisa ukuguguleka kwamathumbu ngenkathi ikhipha ukunyakaza kwama- antigen omzimba emathunjini.
Ngesikhathi i-INN-202 inganciphisa kakhulu izimpawu zesifo se-celiac , akunakwenzeka ukuthi umuntu uzokwazi ukudla amanani angenamkhawulo we-gluten. Okunye ukuvinjelwa kokudla kuyodingeka.
I-US Food Administration and Drug Administration (FDA) ishesha-ilandelela lesi sidakamizwa. Izivivinyo zokwelapha zesigaba sesi-III ziyaqhubeka. Imiphumela yalesilingo ingase itholakale ngesikhathi esithile phakathi nonyaka kuya ku-2018
I-Nexvax2 Vaccine
I-Nexvax2 yiyona kuphela i-candidate yezidakamizwa ezihlose ukugoma abantu ngokumelene nesifo futhi zivumele ukuba babuyele ekudleni okujwayelekile. I-Nexvan2 isuqedile ngempumelelo isivivinyo sokuphepha se-Phase Ib futhi isendleleni yokuthuthela ezinkulingweni ezinkulu zeSigaba II.
I-Nexvax2 ihlonyiswa eklasini elikhulayo lemithi yokwelashwa ehlose ukuphatha abantu asebevele benesifo.
Isekelwe ezimisweni ezifanayo njengendlela yokwelashwa yendabuko yokudonswa kwezidakamizwa ezisetshenziselwa ukwelashwa. Izibonelo zokugoma ezifanayo ziphethwe uphenyo zokwelapha izifo ezibangelwa yi-multiple sclerosis, i-type 1 yesifo sikashukela, ne-arthritis ye-rheumatoid.
I-Nexvax2 isetshenziselwa izakhi zofuzo (DQ2) kubantu abaphethe isifo sofuzo (DQ2) esivela ngamaphesenti angu-90 abantu abanesifo. Uma kunjalo, umgomo ngeke usebenze uma ungenalo i-DQ2,
Ngaphandle kwalokhu, abaphenyi bombuzo oyinhloko abanakho ukuthi imiphumela yomuthi wokugoma ingahlala isikhathi eside kangakanani. Isivivinyo se-Phase Ib sasihilela ukuphindwa okuphindaphindiwe, Nakuba lezo ziphumo zithembise (abantu abaningi bakwazi ukuqeda inselele ye-gluten kunelabo ababeka endaweni ye-placebo), kubonakala ukuthi kubonakala ukuthi umuthi unamandla futhi oqinile kangakanani ngempela.
Ayikho igama okwamanje lapho abacwaningi bezoqala ukuhlolwa kweSigaba II / III.
BL-7010
I-BL-7010 inikeza indlela ehluke ngokuphelele yokwelapha isifo se-celiac. Esikhundleni sokukhomba amathumbu noma impendulo yokuzimela, i-BL-7010 ibopha iphrotheni ngokwayo futhi ivimbela ikhono layo lokubamba.
I-BL-7010 iyi-polymer engeyona imithwalo ekwazi ukufihla i-gluten ezimpilweni ezihlose ukuyidiliza. Ngokufeza lokhu, amasosha omzimba akwazi ukuqala ukuphendula ngokuzenzakalela.
I-gluten ethengiswayo kanye nezidakamizwa zizoxoshwa emzimbeni esitokisini.
Ngemva kokuhlolwa okuphelele kweSigaba I no-II, abakhiqizi bathatha enye indlela futhi baqala ukugqugquzela i-BL-7010 njengokwesekwa kokudla kunokuba imithi yokwelapha. NgoJanuwari 2016, le nkampani yamukelwa imvume ye-European Union futhi njengamanje iqala ukuhlolwa kwe-efficacy emtholampilo ngaphansi kwesigaba se-Class IIb yezokwelapha.
Izwi elivela
Ngesikhathi esethembisayo, akukacaci ukuthi noma iyiphi yalezi zidakamizwa izokwenza ukuthi imakethe. Ekugcineni, noma yikuphi ozobhapathizwa kuzodinga ukugcwalisa izithembiso ezintathu uma kufanele kucatshangelwe.
Bodinga ukuphathwa kalula, ukuhlala isikhathi eside, banikeze amashejuli okufaka isicelo okufanelekile, bebekezeleleke kahle, futhi, okubaluleke kakhulu, mhlawumbe bangabizi.
Ngakho-ke kusekhona okuningi okumele kuphendulwe. Kodwa ngokucwaninga okuqhubekayo nokuqonda kabanzi ngezindlela zalesi sifo , singase sibone usuku lapho singasaphila khona-gluten.
> Umthombo:
> Wingjiranirun, M .; Kelly, C .; kanye neLeffler, D. "Isimo samanje sezifo zeCeliac Developers Drug t." I-American Journal ye-Gastroenterology. 2016; 111 (6): 779-86.